BRCA1 and cancer: For example, it has recently been shown that germline or somatic loss-of-function alterations in BRCA1/2 are associated with tumorigenesis in only a few types of cancer, namely breast, ovarian, prostate, and pancreatic cancers, and that there is little benefit in treating other cancer types that harbor such mutations with PARP inhibitors [144].